Correlations between Carcinoembryonic Antigen, Epidermal Growth Factor and Leptin in Patients with Non-Small-Cell Lung Cancer

• Cuihong Song

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Jie Liao

  Research Laboratory of Medical Experiment and Test Center, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Zihui Deng

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Jinying Zhang

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Hui Xue

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Yongming Li

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Chen Liang

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Ming Han

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Jianhua Li

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

• Guangtao Yan

  Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, 28 Fuxing Road, Beijing 100853, P.R. China

 Objectives:Carcinoembryonic antigen (CEA), epidermal growth factor (EGF) and leptin have been reported to be intimately intertwined in lung carcinogenesis.However, few studies have simultaneously examined these proteins in lung cancer and whether a correlation exist among them remains unclear. Here, we compared the levels of CEA, EGF and leptin in non-small-cell lung cancer (NSCLC) patients and controls and evaluated the possible associations among them.

Methods:97 patients ranged from 30 to 83 years of age were studied. Serum CEA, EGF and leptin levels were determined following a standard protocol. The relationships between these proteins and clinicopathological factors were evaluated by Wilcoxon rank sum or Kruskal-Wallis H test. Spearman rank-correlation were used to determine the correlations among CEA, EGF and leptin. Co-expression of these proteins in NSCLC tissues was examined by immunofluorescence.

Results: Serum CEA and leptin levels in NSCLC patients were significantly higher compared to controls (both P = 0.000), but no statistically significant difference was found for EGF. CEA and EGF were not associated with the tumor-related factors, but leptin was strongly correlated with sex (P = 0.005). Significant correlations among these proteins were found when the patients were categorized into subgroups. Co-expresstion of these proteins was significantly enhanced with lung carcinogenesis.

Conclusions:CEA, EGF and leptin may interplay and play vital roles in the pathogenesis of NSCLC. Besides CEA, the leptin levels were also significantly higher in NSCLC patients than in controls. Determination of preoperative leptin levels may prove useful for screening and predicting NSCLC.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. Cancer J Clin 2010; 60: 277-300. http://dx.doi.org/10.3322/caac.20073

Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 2007; 25: 5785-92. http://dx.doi.org/10.1200/JCO.2007.13.3975

Terzidis A, Sergentanis TN, Antonopoulos J, et al. Elevated Serum Leptin Levels: A Risk Factor for Non-Small-Cell Lung Cancer? Oncology 2009; 76: 19-25. http://dx.doi.org/10.1159/000177952

Ford CHJ, Stokes HJ, Newman CE. Carcinoembryonic antigen and prognosis after radical surgery for lung cancer: immunhistochemical localization and serum levels. Br J Cancer 1981; 44: 145-53. http://dx.doi.org/10.1038/bjc.1981.164

Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012; 76: 138-43. http://dx.doi.org/10.1016/j.lungcan.2011.11.012

Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962; 237: 1555-62.

Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979; 48: 193-216. http://dx.doi.org/10.1146/annurev.bi.48.070179.001205

Mello RA, Ferreira M, Costa S, et al. Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study. Tumor Biol 2012; 33: 1341-48. http://dx.doi.org/10.1007/s13277-012-0382-7

Tseng CL, Wu SY, Wang WH, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008; 29: 3014-22. http://dx.doi.org/10.1016/j.biomaterials.2008.03.033

Agarwal V, Lind MJ, Cawkwell L. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand? Cancer Treat Rev 2011; 37: 533-42. http://dx.doi.org/10.1016/j.ctrv.2010.11.004

Garofalo C and Surmacz E. Leptin and Cancer. J Cell Physiol 2006; 207: 12-22. http://dx.doi.org/10.1002/jcp.20472

Artac M, Altundag K. Leptin and breast cancer: an overview. Med Oncol 2012; 29: 1510-14. http://dx.doi.org/10.1007/s12032-011-0056-0

Goodwin PJ, Ennis M, Fantus IG, et al. Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer? J Clin Oncol 2005; 23: 6037-42. http://dx.doi.org/10.1200/JCO.2005.02.048

Xu YJ, Shao YF, Zhao X, Geng YT, Wang K, Yin M. Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis. J Cancer Res Clin Oncol 2011; 137: 1841-8. http://dx.doi.org/10.1007/s00432-011-1054-5

Alema´n MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 2002; 19: 21-6. http://dx.doi.org/10.1006/cyto.2002.1051

Kerenidi T, Lada M, Tsaroucha A, Georgoulias P, Mystridou P, Gourgoulianis KI. Clinical significance of serum adipokines levels in lung cancer. Med Oncol 2013; 30: 507-14. http://dx.doi.org/10.1007/s12032-013-0507-x

Ribeiro R, Araujo AP, Coelho A, et al. Medeiros: A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer, Eur J Cancer 2006; 42: 1188-93. http://dx.doi.org/10.1016/j.ejca.2006.02.004

Zhang JY, Deng ZH, Liao J. et al. Leptin attenuates cerebral ischemia injury through the promotion of energy metabolism via the PI3K/Akt pathway. J Cerebr Blood F Met 2013; 33: 567-74. http://dx.doi.org/10.1038/jcbfm.2012.202

Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004; 10: 4325-31. http://dx.doi.org/10.1158/1078-0432.CCR-03-0749

Fiorio E, Mercanti A, Terrasi M, et al. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008; 8: 305-15. http://dx.doi.org/10.1186/1471-2407-8-305

Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res 2007; 149: 9-14. http://dx.doi.org/10.1016/j.jss.2007.10.012

• PDF